Implementation of a Multidisciplinary Enhanced Recovery After Surgery (ERAS) Program for Cytoreductive Surgery (CRS) With Hyperthermic Intraperitoneal Chemotherapy (HIPEC)

Cecily Stockley,Antoine Bouchard‐Fortier,Jennifer Mateshaytis,Kadhim Taqi,Lloyd Mack,Gregg Nelson,Michael Chong,Melina Deban
DOI: https://doi.org/10.1002/jso.27931
2024-10-04
Journal of Surgical Oncology
Abstract:Background and Objectives Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can be associated with prolonged hospital stays. A novel Enhanced Recovery After Surgery (ERAS) based on ERAS Society guidelines was designed and implemented. The primary outcome was ERAS compliance. Secondary outcomes included length of stay (LOS) and postoperative complications. Methods A retrospective study on patients who underwent CRS/HIPEC between 2018 and 2022, with ERAS implementation in 2022. Health records were reviewed. Statistical analysis included descriptive statistics, Wilcoxon tests, Student t‐test, and χ2 and binomial negative regression. Health Ethics Research Board approval was obtained. Results Eighty patients underwent CRS/HIPEC: 59 in the pre‐ERAS group and 21 in the post‐ERAS group. Groups were similar in age, comorbidities, and Peritoneal Carcinomatosis Index. ERAS compliance increased from 32.8% to 70.8% (p
oncology,surgery
What problem does this paper attempt to address?